Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
Core Innovation
The document discloses solid-state crystalline forms of a specific RIPK1 inhibitor, (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide (Compound I). It identifies multiple crystalline forms, including anhydrous polymorphs Forms A and B, a hydrate Form C, and solvates Forms D, E, and F. These forms are characterized as distinct solid-state entities.
The crystalline forms are defined and distinguished using characterization criteria including XRPD peak positions, DSC thermal events, and TGA mass-loss ranges where applicable. The document reports that these analytical signatures support identification of each form, and it provides characterization-based descriptions for Forms A through F. This establishes a clear structure-property mapping for the crystalline forms of Compound I.
The document also reports form stability and behavior, including interconversion between Forms A/B/C to Form B under slurry competition, and dynamic vapor sorption showing Forms A and B are non-hygroscopic with very low weight gain up to 95% RH. It further reports physical and chemical stability with no observable form change under storage conditions. Additionally, pharmaceutical compositions containing the forms are described for treating diseases mediated by RIPK1.
Claims Coverage
The partial content includes three independent claims directed to selecting or defining crystalline forms of Compound I: selecting a form among Forms A–F, and identifying single forms Form A, Form B, and Form C. Each independent claim is anchored to the compound’s crystalline form designation and characterization-defined identification.
Crystalline form selection among anhydrous polymorphs, hydrate, and solvates
A crystalline form selected from the group consisting of Form A, Form B, Form C, Form D, Form E, and Form F of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide.
Form A crystalline form
A crystalline form of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, characterized as Form A.
Form B crystalline form
A crystalline form of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, characterized as Form B.
Form C crystalline form
A crystalline form of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, characterized as Form C.
Overall, the claim coverage is focused on crystalline form subject matter for a specific RIPK1 inhibitor: selecting among Forms A–F, and defining specific forms Form A, Form B, and Form C. The provided claim information also ties each named form to analytical characterization signatures, including XRPD and DSC, and optionally TGA, to support identification.
Stated Advantages
Non-hygroscopic behavior reported for Forms A and B, with very low weight gain up to 95% RH.
Physical and chemical stability reported, with no observable form change under storage conditions.
Documented Applications
Treating diseases mediated by RIPK1 by administering an effective amount of the selected crystalline form to a patient.
Interested in licensing this patent?